Florida Leads the Way: Putting Patients First with Common-Sense Cancer Research
By Hotspotnews
In a refreshing display of prioritism over bureaucracy, the State of Florida is taking concrete steps to investigate whether a decades-old, dirt-cheap antiparasitic drug—ivermectin—can help patients battling advanced cancer. At roughly 77 cents a dose, this generic medication stands in stark contrast to the six- and seven-figure price tags that have become routine in modern oncology. Florida’s Cancer Innovation Fund and a forthcoming University of Florida clinical trial represent the kind of practical, patient-centered approach conservatives have long advocated: follow the science, ignore the special interests, and give ordinary Americans every reasonable chance at hope.
The ICONIC Phase 2 study, sponsored by the University of Florida, will examine ivermectin used alongside standard immune checkpoint inhibitors in adults with solid tumors. The trial is carefully designed, focusing first on safety and biological effects rather than making premature claims of cures. It is scheduled to begin recruiting in the coming months. This is not fringe experimentation; it is disciplined research into drug repurposing—an idea that should have bipartisan appeal but has too often been sidelined when the drug in question is inexpensive and off-patent.
Florida’s initiative did not emerge in a vacuum. Public interest surged after high-profile discussions, including actor Mel Gibson’s account on a major podcast of friends who reportedly recovered from stage 4 cancer while using protocols that included ivermectin. Rather than dismiss these reports out of hand or lecture the public about “misinformation,” Florida’s leadership chose a better path: fund rigorous testing. Governor Ron DeSantis and First Lady Casey DeSantis, herself a cancer survivor, have directed significant state resources toward innovative approaches that Big Pharma has little financial incentive to pursue. When a drug costs pennies and cannot be monopolized, the usual market forces that drive research simply do not apply. Government at the state level stepping in to fill that gap is not socialism; it is common sense stewardship of public dollars on behalf of citizens who need options.
For years, patients and families have watched the medical establishment close ranks around expensive patented therapies while treating inexpensive generics with suspicion. Conservatives rightly insist that science must be open to evidence from every direction. If early laboratory and observational signals around ivermectin prove meaningful, millions of patients could benefit without bankrupting their families or the healthcare system. If the signals fade under controlled study, that knowledge is equally valuable. Either outcome advances the truth.
This effort also reflects a broader conservative principle: distrust of captured institutions. During the COVID years, ivermectin became a political football. That history should not permanently taint a legitimate scientific question about its possible role in oncology. Florida is demonstrating that states can lead when federal agencies move too slowly or become overly cautious. By investing in transparent, university-led research, the Sunshine State is modeling how limited, targeted government action can expand freedom of choice for patients rather than restrict it.
Cancer remains one of the most feared diagnoses in American life. Families facing stage 4 disease do not have the luxury of waiting for perfect consensus or the next blockbuster drug priced beyond reach. They need every promising avenue explored with honesty and urgency. Florida’s decision to study low-cost ivermectin is a step in that direction—pragmatic, hopeful, and grounded in the belief that American ingenuity and open inquiry still matter more than institutional gatekeeping.
The results of the upcoming trial will speak for themselves. Until then, credit is due to a state willing to ask hard questions and put patients ahead of profits and politics. That is the kind of leadership the country needs more of.
